Stanford J L, Grange J M
University College London Medical School.
J R Coll Physicians Lond. 1993 Jul;27(3):218-23.
As the end of the twentieth century approaches new methods are needed for the treatment and control of tuberculosis. Vaccination needs to be rethought, and BCG either improved or replaced. Chemotherapy is no longer enough to meet the needs of impoverished countries, non-compliant patients, and increasingly drug-resistant organisms. The next major step forward should logically come from immunology. Following the clear differentiation of two pathways of cellular immune response to mycobacterial challenge, and the recent description of two functional types of helper T cells, ideas of what controls them have allowed the logical development of a potential new vaccine and a new immunotherapy. These are based on a killed environmental organism, Mycobacterium vaccae NCTC 11659. With this simple preparation together with chemotherapy we may be armed as never before to face the inevitable challenge that tuberculosis will present to the twenty first century. Parallels recognised between cell death in tuberculosis and infection with the human immunodeficiency virus open the possibility that the progress made in immunotherapy in tuberculosis might be applicable to HIV. If this proves the case then we may also have control over the latest, and worst, risk factor for tuberculosis at the time we need it most.
随着二十世纪接近尾声,需要有新的方法来治疗和控制结核病。疫苗接种需要重新思考,卡介苗(BCG)要么改进,要么被取代。化疗已不足以满足贫困国家、不依从患者以及耐药性日益增强的病原体的需求。接下来的重大进展从逻辑上来说应该来自免疫学。在明确区分了针对分枝杆菌攻击的两种细胞免疫反应途径,以及最近对两种功能性辅助性T细胞类型的描述之后,关于控制它们的因素的观点使得一种潜在的新疫苗和新免疫疗法得以合理发展。这些都基于一种灭活的环境微生物——母牛分枝杆菌NCTC 11659。有了这种简单的制剂以及化疗,我们或许能够以前所未有的能力应对结核病在二十一世纪必然会带来的挑战。在结核病中的细胞死亡与人类免疫缺陷病毒感染之间发现的相似之处,使得结核病免疫疗法所取得的进展有可能应用于艾滋病病毒(HIV)的可能性成为现实。如果情况确实如此,那么在我们最需要的时候,我们或许也能够控制结核病最新且最严重的风险因素。